Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and Pembrolizumab
2026 ASCO GU
Matthew D. Galsky, MD, FASCO, of Mount Sinai Tisch Cancer Center, discusses findings from the randomized phase III KEYNOTE-B15/EV-304 study, which is evaluating neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab followed by radical cystectomy plus pelvic lymph node dissection vs neoadjuvant chemotherapy followed by radical cystectomy plus pelvic lymph node dissection in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based therapy (Abstract LBA630).
The ASCO Post Staff
Neha Vapiwala, MD, of the University of Pennsylvania, discusses key themes in prostate cancer data presented at this year’s symposium, including personalization of therapy, treatment sequencing considerations, the role of radiopharmaceuticals, long-term radiotherapy results, using AI and associated tools in the clinic, survivorship, and managing quality of life.
Abstracts Mentioned:
EORTC 1333/PEACE-3
ASCENDE-RT
Abstract 215
Abstract 362
Abstract 305
The ASCO Post Staff
Enrique Gallardo, MD, of Parc Taulí University Hospital, presents final overall survival results from the EORTC 1333/PEACE-3 trial, which is a phase III trial evaluating the addition of radium-223 to enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Earlier data from the trial showed that the combination prolonged both radiographic progression–free and overall survival; the new data include a final overall survival analysis and updated safety results (Abstract 15).
The ASCO Post Staff
Anna Clare Wilkins, PhD, MRCP, MBBChir, of The Institute of Cancer Research, discusses the external validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker using data from the phase III CHHiP trial. CHHiP evaluated conventional vs hypofractionated high-dose intensity-modulated radiotherapy for patients with localized prostate cancer (Abstract 308).
The ASCO Post Staff
Maha H.A. Hussain, MD, FASCO, FACP, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, reviews results from the BRCAAway trial, which evaluated the efficacy of abiraterone vs olaparib vs the two agents in combination as first-line therapy for patients with metastatic castration-resistant prostate cancer harboring germline or somatic homologous recombination repair mutations. Progression-free survival results were previously reported; the data presented at this year’s meeting focused on overall survival (Abstract 16).
The ASCO Post Staff
Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, reports on the 15-year survival analysis from the ASCENDE-RT trial, which randomly assigned patients to receive either prostate brachytherapy or the external-beam radiotherapy boost; both arms also received androgen-deprivation therapy. Fifteen-year overall survival and cumulative risk of death from prostate cancer were analyzed (Abstract 306).
